Search

Your search keyword '"Ballescà, Ferran"' showing total 3 results
Start Over Author "Ballescà, Ferran" Publication Type Academic Journals
3 results on '"Ballescà, Ferran"'

1. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

Author

Daudén, Esteban, Llamas-Velasco, Mar, Carretero, Gregorio, Vilar-Alejo, Jaime, Rivera, Raquel, García-Donoso, Carmen, Ferrándiz, Carlos, Carrascosa, José Manuel, Ballescá, Ferrán, Cueva, Pablo de la, Belinchón, Isabel, Gómez-García, Fran J., Jiménez, Rafael, Herrera-Ceballos, Enrique, Herrera-Acosta, Enrique, López-Estebaranz, José Luis, Ruiz-Genao, Diana Patricia, Farrés, Marta Ferrán, Alsina, Mercè, Baniandrés, Ofelia, Nieto, Lula, Sánchez-Carazo, José Luis, Sahuquillo-Torralba, Antonio, Botella-Estrada, Rafael, Marco, Conrad Pujol, Fernández-Freire, Lourdes Rodríguez, Puchades, Almudena Mateu, Menéndez, Ángeles Flórez, Salgado, Laura, Sixto, Beatriz González, Eiris, Noemí, García-Doval, Ignacio, Descalzo Gallego, Miguel Ángel, de Vega Martínez, Marina, de la Cueva, Pablo, Gómez-García, Francisco José, Ferrán-Farrés, Marta, Baniandrés-Rodríguez, Ofelia, Fernández-Freire, Lourdes Rodriguez, Segovia-Muñoz, Eva, and Descalzo, Miguel Angel

Published
2020
Full Text
View/download PDF

2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

Author

Daudén, Esteban, Llamas-Velasco, Mar, Santamaría, Cristina, Carretero, Gregorio, Vilar-Alejo, Jaime, Madrid Álvarez, Blanca, Rivera, Raquel, García-Donoso, Carmen, Gomis, Ma del Mar Onteniente, Batista Cabrera, Diana, Ferrándiz, Carlos, Manuel Carrascosa, José, Ballescá, Ferrán, de la Cueva, Pablo, Molina Mejías, Patricia, Belinchón, Isabel, García Giner, Carlos, Perez, Alfred, Gómez-García, Fran J., Herrera-Ceballos, Enrique, Herrera-Acosta, Enrique, Martínez-García, Eliseo, Sánchez, Cristina, López-Estebaranz, José Luis, Patricia Ruiz-Genao, Diana, García Zamora, Elena, Ferrán Farrés, Marta, Alsina, Mercè, Riera, Josep, Pedregosa Fauste, Sara, Baniandrés, Ofelia, María Nieto Benito, Lula, Molina, Desiree, Sánchez-Carazo, José Luis, Sahuquillo-Torralba, Antonio, Botella-Estrada, Rafael, Pujol Marco, Conrad, Chaparro Aguilera, Natalia, Massó López, Verónica, Rodríguez Fernández-Freire, Lourdes, Mateu Puchades, Almudena, Santos, Sergio, Sáez Belló, Marina, Flórez Menéndez, Ángeles, Salgado, Laura, González Sixto, Beatriz, Abalde, Ma Teresa, Vilanova, Lucia, Perez Mariño, Alexandra, Eiris, Noemí, Prieto Marcos, Vicenta, García-Doval, Ignacio, Ángel Descalzo Gallego, Miguel, de Vega Martínez, Marina, Baniandrés-Rodríguez, Ofelia, Carrascosa, José Manuel, Nieto-Benito, Lula María, Fernández-Freire, Lourdes Rodríguez, Ruiz-Genao, Diana Patricia, Riera-Monroig, Josep, and Descalzo Gallego, Miguel Ángel

Published
2021
Full Text
View/download PDF

3. Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Author

Chicharro, Pablo, Llamas‐Velasco, Mar, Armesto, Susana, Herrera Acosta, Enrique, Vidal, David, Vilarrasa, Eva, Rivera‐Diaz, Raquel, De‐la‐Cueva, Pablo, Martorell‐Calatayud, Antonio, Ballescà, Ferran, Belinchon, Isabel, Carretero, Gregorio, Rodriguez, Lourdes, Romero‐Maté, Alberto, Pujol‐Montcusí, Josep, Salgado, Laura, Sahuquillo‐Torralba, Antonio, Coto‐Segura, Pablo, Baniandrés Rodríguez, Ofelia, and Feltes, Rosa

Subjects
BODY surface area, PSORIASIS, BODY mass index
Abstract

The aim of the study was to assess the long‐term effectiveness and safety of secukinumab in Spanish patients with moderate‐to‐severe psoriasis in a daily practice setting. Nationwide multicenter, observational, retrospective, non‐interventional, single‐cohort study including patients who initiated treatment with secukinumab in daily clinical practice conditions. Subjects were followed for a minimum of 3 months and a maximum of 24 months. Psoriasis Area Severity Index (PASI), Body Surface Area and Physician's Global Assessments were collected at baseline and months 3, 6, 12, 18 and 24 during treatment. Adverse events and reasons for secukinumab withdrawal were collected and classified for analyses. A total of 384 patients were enrolled in the study. Median PASI declined rapidly from 14.3 at baseline to 2.7 at month 3, 2.1 at month 12, and remained low (2.8) at month 24. Within the group of patients with PASI ≥10 at baseline (n = 278), 58.3%, 60.4% and 56.5% achieved a PASI90 response at months 3, 12 and 24, respectively. As for absolute PASI, 86.5%, 69.5%, 42.7% and 37% achieved PASI <5, < 3, < 1 and 0, respectively, at month 3. Secukinumab was more effective in biologic‐naïve patients and in those with lower Body Mass Index. Secukinumab presented a good long‐term safety profile. Secukinumab was effective and safe in a routine clinical setting, in a large cohort of patients with moderate‐to‐severe plaque psoriasis, in the short‐, medium‐ and long‐term (up to 24 months). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results